Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

FS222, a CD137/PD-L1 tetravalent bispecific antibody exhibits low toxicity and anti-tumor activity in colorectal cancer models

(2020) Matthew A Lakins et al.   CLINICAL CANCER RESEARCH

CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

(2020) Álvaro Teijeira et al.   IMMUNITY

Preliminary population pharmacokinetics supports phase II dose selection for masked anti-PD-L1 antibody CX-072.

(2020) Mark Stroh et al.   JOURNAL OF CLINICAL ONCOLOGY

Evidence of intratumoral localization, activation, and immunomodulatory effect of CX-072, a probody therapeutic targeting PD-L1, in a phase I/II trial.

(2020) Susan Lyman et al.   JOURNAL OF CLINICAL ONCOLOGY

Model‐Informed Drug Development of the Masked anti‑PD‑L1 Antibody CX‐072

(2020) Mark Stroh et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis

(2020) Iñaki Etxeberria et al.   ESMO Open

Antibody to CD137 activated by extracellular adenosine triphosphate is tumor selective and broadly effective in vivo without systemic immune activation

(2020) Mika Kamata-Sakurai et al.   Cancer Discovery

The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation

(2019) Olga Vasiljeva et al.   BIOLOGICAL CHEMISTRY

The promise of neoadjuvant immunotherapy and surgery for cancer treatment

(2019) Jake S O'Donnell et al.   CLINICAL CANCER RESEARCH

CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.

(2019) Aung Naing et al.   JOURNAL OF CLINICAL ONCOLOGY

Twists and turns to translating 4-1BB cancer immunotherapy

(2019) Miguel F. Sanmamed et al.   Science Translational Medicine

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

(2019) Christina Claus et al.   Science Translational Medicine

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

(2019) Karen A. Autio et al.   CLINICAL CANCER RESEARCH

VISTA is an acidic pH-selective ligand for PSGL-1

(2019) Robert J. Johnston et al.   NATURE

Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

(2019) Iñaki Etxeberria et al.   CANCER CELL

Antibody prodrugs for cancer

(2019) W. Michael Kavanaugh   EXPERT OPINION ON BIOLOGICAL THERAPY

Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27–Dependent Pathway

(2018) Todd Bartkowiak et al.   CLINICAL CANCER RESEARCH

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

(2018) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

The promise and challenges of immune agonist antibody development in cancer

(2018) Patrick A. Mayes et al.   NATURE REVIEWS DRUG DISCOVERY

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Preliminary interim results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic (Pb-Tx) CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors.

(2018) Rachel E. Sanborn et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018)   NEW ENGLAND JOURNAL OF MEDICINE

The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8 + T cells in the tumor microenvironment

(2017) Jason B. Williams et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Intratumoral CD8 + T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity

(2017) Brendan L. Horton et al.   Cancer Immunology Research

Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?

(2016) Bettina Weigelin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

(2016) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses

(2016) Lindsay K. Ward-Kavanagh et al.   IMMUNITY

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD-1 and Anti-CD137 Monoclonal Antibodies

(2016) Arantza Azpilikueta et al.   Journal of Thoracic Oncology

Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy

(2016) I. Melero et al.   Cancer Discovery

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

(2016) J. Liu et al.   Cancer Discovery

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

(2015) Bettina Weigelin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies

(2014) M. Dai et al.   CLINICAL CANCER RESEARCH

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

(2013) L. R. Desnoyers et al.   Science Translational Medicine

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

(2012) Timothy S. Fisher et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunotherapeutic Synergy Between Anti-CD137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL-12

(2012) José I Quetglas et al.   MOLECULAR THERAPY

Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes

(2011) A. Palazon et al.   CANCER RESEARCH

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

(2010) Juan Dubrot et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY